269 related articles for article (PubMed ID: 29687160)
1. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
3. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S; Yasumizu Y; Ito K; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Tanaka N; Mizuno R; Oya M
Clin Genitourin Cancer; 2016 Dec; 14(6):e575-e583. PubMed ID: 27102405
[TBL] [Abstract][Full Text] [Related]
4. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
Tan HS; Li H; Hong YW; Toh CK; Wong A; Lopes G; Tay MH; Chan A; Yao X; Tang T; Ng QS; Kanesvaran R; Chau NM; Tan MH
Clin Genitourin Cancer; 2015 Aug; 13(4):e285-e295. PubMed ID: 25541325
[TBL] [Abstract][Full Text] [Related]
6. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
7. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
9. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
Buti S; Donini M; Bersanelli M; Gattara A; Leonardi F; Passalacqua R
Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
11. Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Iwamoto K; Tachibana H; Yoshida K; Omae K; Iizuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2018 Jul; 48(7):667-672. PubMed ID: 29860353
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
[TBL] [Abstract][Full Text] [Related]
13. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of sarcopenia and decreased relative dose intensity during the initial two cycles of first-line sunitinib for metastatic renal cell carcinoma.
Lee CH; Ku JY; Seo WI; Park YJ; Chung JI; Kim W; Park TY; Ha HK
J Chemother; 2021 Jul; 33(4):245-255. PubMed ID: 33412998
[TBL] [Abstract][Full Text] [Related]
16. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
Miyake H; Harada K; Miyazaki A; Fujisawa M
Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
18. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
20. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
